Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 14, 2020 - Issue
Submit an article Journal homepage
153
Views
20
CrossRef citations to date
0
Altmetric
Original Research

Treatment with a PPAR-γ Agonist Protects Against Hyperuricemic Nephropathy in a Rat Model

Xin Wang1 Department of Nephrology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, People’s Republic of China
,
Jin Deng2 Department of Nephrology, The First Affiliated Hospital of University of South China, Hengyang, People’s Republic of China
,
Chongxiang Xiong1 Department of Nephrology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, People’s Republic of China
,
Haishan Chen1 Department of Nephrology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, People’s Republic of China
,
Qin Zhou1 Department of Nephrology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, People’s Republic of China
,
Yue Xia1 Department of Nephrology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, People’s Republic of China
,
Xiaofei Shao1 Department of Nephrology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, People’s Republic of China
&
Hequn Zou1 Department of Nephrology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, People’s Republic of ChinaCorrespondence[email protected]
 show all
Pages 2221-2233 | Published online: 08 Jun 2020

Citations (20)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Jing Huang, Zhijian Lin, Yu Wang, Xueli Ding & Bing Zhang. (2023) Wuling San Based on Network Pharmacology and in vivo Evidence Against Hyperuricemia via Improving Oxidative Stress and Inhibiting Inflammation. Drug Design, Development and Therapy 17, pages 675-690.
Read now
Peng Du, Ming Chen, Changcai Deng & Chonggui Zhu. (2022) microRNA-199a downregulation alleviates hyperuricemic nephropathy via the PPARγ/β-catenin axis. Journal of Receptors and Signal Transduction 42:4, pages 373-381.
Read now

Articles from other publishers (18)

Pengfei Meng, Yanxin Wang, Yumeng Huang, Tong Liu, Mingxia Ma, Jiaojiao Han, Xiurong Su, Wenjun Li, Yanbo Wang & Chenyang Lu. (2024) A strategy to boost xanthine oxidase and angiotensin converting enzyme inhibitory activities of peptides via molecular docking and module substitution. Food Chemistry 442, pages 138401.
Crossref
Yu Xiang, Zhuo Yuan, Qichuan Deng, Linshen Xie, Dongke Yu & Jianyou Shi. (2024) Potential therapeutic medicines for renal fibrosis: Small-molecule compounds and natural products. Bioorganic Chemistry 143, pages 106999.
Crossref
Kaiqing Li, Yanchun Ma, Xue Xia, Huili Huang, Jianing Li, Xiaoxin Wang, Yang Gao, Shuxiang Zhang, Tong Fu & Ying Tong. (2023) Possible correlated signaling pathways with chronic urate nephropathy: A review. Medicine 102:32, pages e34540.
Crossref
Kexin Lin, Xiaorui Kong, Xufeng Tao, Xiaohan Zhai, Linlin Lv, Deshi Dong, Shilei Yang & Yanna Zhu. (2023) Research Methods and New Advances in Drug–Drug Interactions Mediated by Renal Transporters. Molecules 28:13, pages 5252.
Crossref
Seong-Kyu Kim, Jung-Yoon Choe, Ji-Won Kim & Ki-Yeun Park. (2023) HMG-CoA Reductase Inhibitors Suppress Monosodium Urate-Induced NLRP3 Inflammasome Activation through Peroxisome Proliferator-Activated Receptor-γ Activation in THP-1 Cells. Pharmaceuticals 16:4, pages 522.
Crossref
Peng Liu, Guijie Ma, Yang Wang, Lifan Wang & Ping Li. (2023) Therapeutic effects of traditional Chinese medicine on gouty nephropathy: Based on NF-κB signalingpathways. Biomedicine & Pharmacotherapy 158, pages 114199.
Crossref
Junxia Feng, Meizhi Lu, Wenhao Li, Jingchun Li, Ping Meng, Zukai Li, Xuejuan Gao & Yunfang Zhang. (2022) PPARγ alleviates peritoneal fibrosis progression along with promoting GLUT1 expression and suppressing peritoneal mesothelial cell proliferation. Molecular and Cellular Biochemistry 477:7, pages 1959-1971.
Crossref
Carla Pou Casellas, Katja Jansen, Maarten B. Rookmaaker, Hans Clevers, Marianne C. Verhaar & Rosalinde Masereeuw. (2022) Regulation of solute carriers oct2 and OAT1/3 in the kidney: a phylogenetic, ontogenetic, and cell dynamic perspective. Physiological Reviews 102:2, pages 993-1024.
Crossref
Jianjun Gao & Zhaoyan Gu. (2022) The Role of Peroxisome Proliferator-Activated Receptors in Kidney Diseases. Frontiers in Pharmacology 13.
Crossref
Zhi-Lin Luan, Cong Zhang, Wen-Hua Ming, Ying-Zhi Huang, You-Fei Guan & Xiao-Yan Zhang. (2022) Nuclear receptors in renal health and disease. eBioMedicine 76, pages 103855.
Crossref
Birui Shi, Yan Zhang, Baolin Huang, Huiping Lin, Qiong Zhou, Yujue Wang, Zheng Cai & Menghua Liu. (2022) The System Profile of Renal Drug Transporters in Tubulointerstitial Fibrosis Model and Consequent Effect on Pharmacokinetics. Molecules 27:3, pages 704.
Crossref
Peng Liu, Chen Wang, Yun Wang, Honghong Zhang, Baoli Liu & Xinping Qiu. (2021) Zishen Qingre Tongluo Formula Improves Renal Fatty Acid Oxidation and Alleviated Fibrosis via the Regulation of the TGF-β1/Smad3 Signaling Pathway in Hyperuricemic Nephrology Rats. BioMed Research International 2021, pages 1-10.
Crossref
Wei Zou, Birui Shi, Ting Zeng, Yan Zhang, Baolin Huang, Bo Ouyang, Zheng Cai & Menghua Liu. (2021) Drug Transporters in the Kidney: Perspectives on Species Differences, Disease Status, and Molecular Docking. Frontiers in Pharmacology 12.
Crossref
Lan Li, Dongqi Cheng, Xingxing An, Guangneng Liao, Ling Zhong, Jingping Liu, Younan Chen, Yujia Yuan & Yanrong Lu. (2021) Mesenchymal stem cells transplantation attenuates hyperuricemic nephropathy in rats. International Immunopharmacology 99, pages 108000.
Crossref
Gábor Kökény, Laurent Calvier & Georg Hansmann. (2021) PPARγ and TGFβ—Major Regulators of Metabolism, Inflammation, and Fibrosis in the Lungs and Kidneys. International Journal of Molecular Sciences 22:19, pages 10431.
Crossref
Bryce A. Jones, Xiaoxin X. Wang, Komuraiah Myakala & Moshe Levi. (2021) Nuclear Receptors and Transcription Factors in Obesity-Related Kidney Disease. Seminars in Nephrology 41:4, pages 318-330.
Crossref
Yongmei Li, Zean Zhao, Jian Luo, Yanqing Jiang, Lu Li, Yanyu Chen, Leqi Zhang, Qinghua Huang, Ying Cao, Pingzheng Zhou, Ting Wu & Jianxin Pang. (2021) Apigenin ameliorates hyperuricemic nephropathy by inhibiting URAT1 and GLUT9 and relieving renal fibrosis via the Wnt/β-catenin pathway. Phytomedicine 87, pages 153585.
Crossref
Yanzuo Le, Xie Zhou, Jiawen Zheng, Fangmiao Yu, Yunping Tang, Zuisu Yang, Guofang Ding & Yan Chen. (2020) Anti-Hyperuricemic Effects of Astaxanthin by Regulating Xanthine Oxidase, Adenosine Deaminase and Urate Transporters in Rats. Marine Drugs 18:12, pages 610.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.